

# Sudden Cardiac Arrest in the Young

David Weiland, MD

Pediatric Cardiology and Electrophysiology

Ochsner Medical Center Hospital for Children

# Objectives

- Discuss incidence and prevalence of Sudden Cardiac Arrest (SCA)
- Review causes of SCA
- Describe measures to screen for and prevent SCA in the young
- Provide resources for healthcare providers caring for patients with history or risk of SCA

# Disclosures

- No disclosures

# What is Sudden Cardiac Arrest?

- SCA is a condition in which the heart abruptly stops providing cardiac output
- Most commonly due to ventricular fibrillation or Torsades de Pointe, but can also be due to bradycardic conditions such as asystole, sinus node arrest, or atrioventricular block

# Definitions and Acronyms

- SCA that results in death is **sudden cardiac death, or SCD**
- Heritable syndromes that result in SCA or SCD are referred to as **sudden arrhythmic death syndromes (SADS)**
- Sudden death of unclear cause is referred to **as sudden unexplained death** (SUD, or SUDi if under 1 year old)

Wally Pontiff remains an LSU folk hero at 10-year anniversary of death

**Bronny James**

**Soccer defect that on-field spokesperson**

Eriksen, a 29-year-old midfielder, "was

**Buffalo Bills' Dan Johnson likely healthy before**

The right hit at the wrong time may have triggered a rare phenomenon known as commotio cordis, heart experts suggest.



**congenital heart cardiac arrest, a**


for further examination," the

**heart was most** ...st

# SCA Statistics


- 210,000 deaths from sudden cardiac arrest per year (all ages and causes) (SADS Foundation)
- 1:200,000 HS athletes die of SCA (JAMA)
- 10-12% of SIDS may be related to Long QT Syndrome
- Long QT Syndrome approximately 3x more common than childhood leukemia (SADS Foundation)

# Causes of SCA in the Young





# Long QT Syndrome

- Originally named based on clinical features and heritance pattern
  - AD: Romano-Ward Syndrome
  - AR with hearing loss: Jervell-Lange-Nielsen Syndrome
- Now named based on affected gene
  - LQTS 1 through 17; >600 individual mutations so far identified



# Most Common Forms of LQTS





**FIGURE 93.1** Distribution of mutation carriers in the two main potassium ( $K^+$ ) channel genes ( $KCNQ1$  and  $KCNH2$ ; in blue) and in the sodium ( $Na^+$ ) channel gene ( $SCN5A$ ; in red), for four different populations: long QT syndrome (LQTS) adult patients, LQTS infants with life-threatening arrhythmias in utero or within the first year of life, intrauterine fetal demises (IUFDs), and sudden infant death syndrome (SIDS) victims.

The distribution of variants between the potassium and sodium channel genes is similar in SIDS, IUFD, and LQTS infant populations, all significantly different from the adults ( $p < .0005$ ). From Crotti L, Ghidoni A, Insolia R, Schwartz PJ. The role of the cardiac sodium channel in perinatal early infant mortality. *Card Electrophysiol Clin*. 2014;6:749-759.

# Diagnosing LQTS

- Diagnosis made based on clinical and molecular criteria
- Genetic testing is useful for:
  - Confirming suspected disease (75-80% gene identified in LQTS)
  - Screening asymptomatic family members to assess future risk
  - Provide potential prognostic guidance related to clinical LQTS diagnosis

			Points
Electrocardiographic Findings <sup>a</sup>			
A	QTc <sup>b</sup>	≥480 ms	3
		460–479 ms	2
		450–459 (male) ms	1
B	QTc <sup>b</sup> 4th minute of recovery from exercise stress test ≥ 480 ms		1
C	Torsades de pointes <sup>c</sup>		2
D	T wave alternans		1
E	Notched T wave in three leads		1
F	Low heart rate for age <sup>d</sup>		0.5
Clinical History			
A	Syncope <sup>e</sup>	With stress	2
		Without stress	1
B	Congenital deafness		0.5
Family History			
A	Family members with definite LQTS <sup>c</sup>		1
B	Unexplained sudden cardiac death below age 30 among immediate family members <sup>e</sup>		0.5

SCORE:

≤1 point: low probability of LQTS

1.5–3 points: intermediate probability of LQTS

≥3.5 points: high probability

# Treatment Specific to LQTS

- **Beta-blockade**

- Nadolol (1-1.5 mg/kg/day) or propranolol (3-4 mg/kg/day) specifically
- Greatly reduces arrhythmia risk; compliance is crucial


- Left Cardiac Sympathetic Denervation, Pacing, and ICD implant may be needed; based on patient characteristics and tolerance of therapy

# Treatment Specific to LQTS

- Asymptomatic carriers (“gene positive, phenotype negative”) have lower risk of ventricular arrhythmias (VA’s), but beta-blockade and cardiology follow up recommended
- Exercise restriction is controversial
  - Most agree with some form of competitive sport limitation for LQT1, but for other types with less adrenergic-related arrhythmias, joint decision making is generally advised.


# Hypertrophic Cardiomyopathy (HCM)


- Genetic disease effecting cardiac myocytes, resulting in “extensive areas of myocyte disarray” resulting in a “chaotic architecture.”
  - This results in areas of myocardial fibrosis and scarring, which is proarrhythmic.
  - That said, the triggers for lethal VA's are poorly understood



# Hypertrophic Cardiomyopathy

- Relatively high prevalence in the population, **estimates 1:500 to 1:200 individuals**
- **Most common cause of SCD in the young**, including competitive athletes
  - HOWEVER, HCM-related SCA events occur in a small minority of patients (~5%); other adverse cardiac complications more common (AF, heart failure)
- SCD risk difficult to predict, but considered 1-1.5%/year
  - SCD risk skews younger rather than older






# Hypertrophic Cardiomyopathy

- **Autosomal Dominant** genetic inheritance pattern; 50% chance of passing risk to offspring
- Because of the volume of information regarding SCA in athletes with HCM, **competitive athletics are generally prohibited**

# Treatment of HCM

- Overall treatment requires comprehensive approach, with regards to outflow tract obstruction, heart failure, anticoagulation need, and prevention of SCA
- **No drug therapy is effective for preventing SCA**
- ICD implantation is the only measure proven to prevent SCA


# Patient Selection for ICD Implant



# Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)


gene	Locus	Inheritance	No. of mutations identified	Phenotype	Frequency
RYR2	1q42-43	Autosomal dominant	>130	CPVT (exon 3 deletion: sinoatrial node, atrioventricular node dysfunction, atrial fibrillation, atrial standstill, dilated cardiomyopathy)	≈60%
CASQ2	1p13.3-p11	Autosomal recessive	12	CPVT	<5%
TRDN	6q22-23	Autosomal recessive	3	CPVT	<5%
Unknown	7p14-22	Autosomal recessive	Not applicable	CPVT, mild QTc interval prolongation	Unknown
KCNJ2	17q24.3	Autosomal dominant		CPVT phenocopy	<5%

10



16

Ventricular Fib  
Tachycardia (1:  
11/04/20 04:03:





Summary Events Patient Events PVI, VF, TdP



Additional Strips




ricular






# CPVT Treatment

- Beta-blocker is primary therapy
- Competitive athletics prohibited



# Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

- Inherited (AD) cardiomyopathy characterized by VA's, increased risk of SCD, and abnormalities of the right ventricular structure and function
- Myocyte replacement with fibro-fatty infiltrate due to malfunction of "adherence" proteins



# ARVC

- Prevalence 1:5000, presentation generally second to fifth decade of life
- **Syncope**, palpitations, SCD are common presentations
- **Family history**

# ARVC

- Clinical diagnosis made based on combination of imaging, electrocardiogram, genetic, histologic, and family history findings
- Treatment based on cardiac function and symptoms, heart failure management and ICD implant as indicated
- **Competitive athletics is prohibited**

# Brugada Syndrome

JACC Vol. 20, No. 6  
November 15, 1992:1391-6

1391

---

## **Right Bundle Branch Block, Persistent ST Segment Elevation and Sudden Cardiac Death: A Distinct Clinical and Electrocardiographic Syndrome**

### **A Multicenter Report**

**PEDRO BRUGADA, MD, JOSEP BRUGADA, MD\*†**


*Aalst, Belgium and Barcelona, Spain*


# Brugada Syndrome

- Best estimate of prevalence is 1:2000 **worldwide**
  - Varies in different populations (**Highest in SE asia**)
- Brugada pattern can be transient
- **Fever** tends to bring out Brugada pattern, and subsequently increases arrhythmia risk
- **VA's** tend to be at rest; exercise restriction not generally warranted
- Risk stratification difficult to assess

# Comotio Cordis

- Sudden cardiac arrest/death due to blunt (nonpenetrating) precordial impact
- Prevalence unknown; 10-20 reported per year
- Mechanism not entirely clear; timing within the cardiac cycle appears to be a significant factor





# Wolff-Parkinson-White Syndrome

- Most common presentation is SVT
  - Abrupt onset palpitations, lightheadedness, chest pain with tachycardia
- WPW is a **rare** cause of SCA, with risk estimated at 0.13% per year
  - Mechanism generally considered rapidly conducted AF, but this may not account for all cases
- Risk stratification remains elusive; **in most cases, catheter-based electrophysiology study recommended for risk assessment and therapeutic ablation as indicated**

# Idiopathic Ventricular Fibrillation (IVF)

- “a resuscitated cardiac arrest victim... with documentation of VF, in whom cardiac, respiratory, metabolic, and toxicological etiologies have been excluded” (2013 HRS/EHRA/APQRS definition)
- Multiple theories and areas of research focusing on new diagnoses that may explain IVF
- ICD implant generally advised
- Genetic evaluation recommended



## Arrhythmogenic right ventricular cardiomyopathy in Boxer dogs: the diagnosis as a link to the human disease

[ANNINA S. VISCHER](#),<sup>1,2</sup> [DAVID J. CONNOLLY](#),<sup>3</sup> [CAROLINE J. COATS](#),<sup>1</sup> [VIRGINIA LUIS FUENTES](#),<sup>3</sup>  
[WILLIAM J. MCKENNA](#),<sup>4</sup> [SILVIA CASTELLETTI](#),<sup>1,5</sup> and [ANTONIOS A. PANTAZIS](#)<sup>1,6</sup>

# Strategies to Prevent Sudden Cardiac Death

Screening for Risk Factors



Treatment of Sudden Cardiac Arrest

# Screening for Risk Factors

- History of **syncope, especially exertional**
- Family history of early “heart attacks” or cardiac arrest (<40-50 years old, especially if multiple)
- Family history of unexplained deaths
  - Single car wrecks
  - Drowning in people who otherwise swim well
- Palpitations, chest pain are very nonspecific, but lean toward evaluation if there are questions

# Screening for Risk Factors

Life threatening cardiac arrhythmia and sudden death during electronic gaming: An international case series and systematic review



♥ Investigate syncope occurring during electronic gaming



Consider counselling regarding safe participation in electronic gaming after a pro-arrhythmic cardiac diagnosis

# Standardized Diagnostic Screening

## METHODS

We prospectively studied sudden deaths among athletes and nonathletes (35 years of age or less) in the Veneto region of Italy from 1979 to 1996. The causes of sudden death in both populations were compared, and the pathological findings in the athletes were related to their clinical histories and electrocardiograms. Cardiovascular reasons for disqualification from participation in sports were investigated and follow-up was performed in a consecutive series of 33,735 young athletes who underwent preparticipation screening in Padua, Italy, during the same period.

## RESULTS

Of 269 sudden deaths in young people, 49 occurred in competitive athletes (44 male and 5 female athletes; mean [ $\pm$ SD] age, 23 $\pm$ 7 years). The most common causes of sudden death in athletes were arrhythmogenic right ventricular cardiomyopathy (22.4 percent), coronary atherosclerosis (18.4 percent), and anomalous origin of a coronary artery (12.2 percent). Hypertrophic cardiomyopathy caused only 1 sudden death among the athletes (2.0 percent) but caused 16 sudden deaths in the nonathletes (7.3 percent). Hypertrophic cardiomyopathy was detected in 22 athletes (0.07 percent) at preparticipation screening and accounted for 3.5 percent of the cardiovascular reasons for disqualification. None of the disqualified athletes with hypertrophic cardiomyopathy died during a mean follow-up period of 8.2 $\pm$ 5 years.

## CONCLUSIONS

The results show that hypertrophic cardiomyopathy was an uncommon cause of death in these young competitive athletes and suggest that the identification and disqualification of affected athletes at screening before participation in competitive sports may have prevented sudden death.

Not screened (non-athletes  
(???)

220

SCA:  
269

**TABLE 2. CAUSES OF SUDDEN DEATH IN ATHLETES AND NONATHLETES 35 YEARS OF AGE OR LESS IN THE VENETO REGION OF ITALY, 1979 TO 1996.**

CAUSE	ATHLETES (N=49)	NONATHLETES (N=220)	TOTAL (N=269)
	number (percent)		
Arrhythmogenic right ventricular cardiomyopathy	11 (22.4)	18 (8.2)*	29 (10.8)
Atherosclerotic coronary artery disease	9 (18.4)	36 (16.4)	45 (16.7)
Anomalous origin of coronary artery	6 (12.2)	1 (0.5)†	7 (2.6)
Disease of conduction system	4 (8.2)	20 (9.1)	24 (8.9)
Mitral-valve prolapse	5 (10.2)	21 (9.5)	26 (9.7)
Hypertrophic cardiomyopathy	1 (2.0)	16 (7.3)	17 (6.3)
Myocarditis	3 (6.1)	19 (8.6)	22 (8.2)
Myocardial bridge	2 (4.1)	5 (2.3)	7 (2.6)
Pulmonary thromboembolism	1 (2.0)	3 (1.4)	4 (1.5)
Dissecting aortic aneurysm	1 (2.0)	11 (5.0)	12 (4.5)
Dilated cardiomyopathy	1 (2.0)	9 (4.1)	10 (3.7)
Other	5 (10.2)	61 (27.7)	66 (24.5)

Screened:  
3,735

ineligible for  
Sports:  
621  
(22 HCM)

\*P=0.008 for the comparison with the athletes.

†P<0.001 for the comparison with the athletes.




## Heart Screening Consists Of:

- Online Registration
- Personal & Family Heart History
- Height, Weight & Blood Pressure Measurements
- 12-lead Electrocardiogram (ECG)
- Auscultation (listening to heart)
- Limited Echocardiogram for those with abnormal results or risk factors
- Results Interpreted by Physician
- Registrants will learn Hands-Only CPR & AED use


*Screening protocol may vary per organization. Screening event does not establish a patient/doctor relationship.*

FEB  
2025



# Treatment of Sudden Cardiac Arrest

- Regardless of change in policy or practice, screening will never achieve 100% identification of possible sudden cardiac arrest conditions
- Awareness of and improved response to SCA
  - CPR training
  - AED availability and use




# Education, Awareness, and Advocacy

English



SADS Conditions If You Suspe



MISSISSIPPI LEGISLATURE

2023 Regular Session

To: Public Health and Welfare; Appropriations

By: Senator(s) Hopson, Jackson, McCaughn

## Senate Bill 2750

*(As Sent to Governor)*

AN ACT TO CREATE NEW SECTION 41-60-34, MISSISSIPPI CODE OF 1972, TO ESTABLISH THE AUTOMATED EXTERNAL DEFIBRILLATORS IN PUBLIC AND CHARTER SCHOOLS GRANT PROGRAM TO BE ADMINISTERED BY THE DEPARTMENT OF HEALTH FOR THE PURPOSE OF PROVIDING FUNDS TO ENTITIES TO SUPPLY AEDS IN PUBLIC AND CHARTER SCHOOLS; TO REQUIRE THE DEPARTMENT TO PROMULGATE RULES AND REGULATIONS FOR THE PROGRAM; TO SET CERTAIN REQUIREMENTS OF THE PROGRAM; AND FOR RELATED PURPOSES.

Join us in November 2024 for an opportunity to learn from the country's top medical experts, hear about the latest research, and connect with others.



# Resources

- Pediatric and Adult Congenital Electrophysiology Society (PACES)
- SADS.org
- Project ADAM
  - CodeAna.org
- Parent Heart Watch
- Crediblemeds.org
  - LQTS and BrS drug reference

**Thank you!**

# References Not Listed in Slides

- Zipes et al., "Cardiac Electrophysiology: From Cell to Bedside, 7<sup>th</sup> Edition." 2018, Elsevier